Presentation is loading. Please wait.

Presentation is loading. Please wait.

Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled.

Published byOpal Warren Modified over 5 years ago

Similar presentations

Presentation on theme: "Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled."— Presentation transcript:

1 Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial  Filip Jansåker, Sara Thønnings, Frederik Boëtius Hertz, Thomas Kallemose, Jan Værnet, Lars Bjerrum, Thomas Benfield, Niels Frimodt- Møller, Jenny Dahl Knudsen  EClinicalMedicine  Volume 12, Pages (July 2019) DOI: /j.eclinm Copyright © Terms and Conditions

2 Fig. 1 Study flowchart * 125 With baseline bacteriuria (69.4%). † 122 With baseline bacteriuria (64.9%). ‡ No clinical nor bacteriological follow-up data received. § Follow-up questionnaire missing in 8 and 6 participants in 5-day and 3-day arm, respectively. Note: The number of cases assessed for eligibility at General Practitioner Clinics were not recorded because of financial and logistics imitations. EClinicalMedicine  , 62-69DOI: ( /j.eclinm ) Copyright © Terms and Conditions

3 Fig. 2 Symptom resolution over time.
The cumulative UTI symptom score (i.e. for the symptoms dysuria, frequency and urgency) was calculated daily. Each symptom was scored 0–3 points (i.e. none, mild, moderate or severe) daily in the participant reported diary. EClinicalMedicine  , 62-69DOI: ( /j.eclinm ) Copyright © Terms and Conditions

Download ppt "Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled."

Similar presentations

Volume 50, Issue 3, Pages (September 2006)

Volume 50, Issue 3, Pages (September 2006)
Volume 35, Issue 4, Pages (August 2016)

Volume 35, Issue 4, Pages (August 2016)
Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study  Uwe Kern, MD, Bernd Altkemper,
Volume 357, Issue 9273, Pages (June 2001)

Volume 357, Issue 9273, Pages (June 2001)
Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative

Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 17, Issue 8, Pages (December 2014)

Volume 17, Issue 8, Pages (December 2014)
Steven J. Linton, Alan E. Fruzzetti  Scandinavian Journal of Pain 

Steven J. Linton, Alan E. Fruzzetti  Scandinavian Journal of Pain 
Volume 376, Issue 9734, Pages (July 2010)

Volume 376, Issue 9734, Pages (July 2010)
Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990  Niels Frimodt-Møller, Frank Espersen, Peter Skinhøj, Vibeke Thamdrup Rosdahl 

Epidemiology of Staphylococcus aureus bacteremia in Denmark from 1957 to 1990  Niels Frimodt-Møller, Frank Espersen, Peter Skinhøj, Vibeke Thamdrup Rosdahl 
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative

Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Cryptococcosis—the impact of delay to diagnosis

Cryptococcosis—the impact of delay to diagnosis
Volume 67, Issue 1, Pages (January 2015)

Volume 67, Issue 1, Pages (January 2015)
Volume 54, Issue 6, Pages (December 2008)

Volume 54, Issue 6, Pages (December 2008)
A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb  J.S. Davis, C. Mackrow,

A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb  J.S. Davis, C. Mackrow,
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Similar presentations

Ads by Google